Stay updated on PD-L1+ NSCLC Coformulation vs Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the PD-L1+ NSCLC Coformulation vs Pembrolizumab Clinical Trial page.

Latest updates to the PD-L1+ NSCLC Coformulation vs Pembrolizumab Clinical Trial page
- ChecktodayChange DetectedA site-wide NIH banner announces updates and FAQs about the agency’s transition from the term “Artificial Intelligence” to “Super Intelligence.”SummaryDifference0.2%

- Check7 days agoChange DetectedThe site footer now identifies the platform as revision v3.7.2 instead of v3.7.1.SummaryDifference0.0%

- Check14 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.0%

- Check35 days agoChange DetectedOn 2026-09-17 the study record was updated to revision v3.7.0, introducing Business Reasons and new status fields (Study Status and Recruitment Status). The previous Completed entry from revision v3.6.6 was removed on 2026-06-26.SummaryDifference0.2%

- Check56 days agoChange DetectedThe version history now shows the current release as Revision: v3.6.6, replacing the previous Revision: v3.6.5 in the history.SummaryDifference0.0%

- Check77 days agoChange DetectedThe page footer now shows Revision: v3.6.5, replacing Revision: v3.6.4. This reflects a software version update rather than changes to study data or page content.SummaryDifference0.0%

Stay in the know with updates to PD-L1+ NSCLC Coformulation vs Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PD-L1+ NSCLC Coformulation vs Pembrolizumab Clinical Trial page.